Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NurExone BiologicFRA:J90 +13.88%38 Debt-to-EBITDA is -0.01 as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 302 Biotechnology companies, NurExone Biologic ranks worse than 331125.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for NurExone Biologic's Debt-to-EBITDA or its related term are showing as below:
FRA:J90'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.64 Med: -0.01 Max: -0.01
Current: -0.01
During the past 5 years, the highest Debt-to-EBITDA Ratio of NurExone Biologic was -0.01. The lowest was -0.64. And the median was -0.01.
FRA:J90's Debt-to-EBITDA is ranked worse than 100% of 302
companies
in the Biotechnology industry
Industry Median: 1.29
vs FRA:J90: -0.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NurExone Biologic Debt-to-EBITDA Related Terms
NurExone Biologic Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for NurExone Biologic's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J90 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, NurExone Biologic's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NurExone Biologic Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NurExone Biologic's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NurExone Biologic's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
NurExone Biologic (FRA:J90) has a Debt-to-EBITDA of -0.01 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NurExone Biologic. According to the industry distribution chart, NurExone Biologic ranks #999999 out of 302 companies in the Biotechnology industry.
Is NurExone Biologic's Debt-to-EBITDA too high?
NurExone Biologic's current Debt-to-EBITDA is -0.01. Based on the distribution chart, NurExone Biologic ranks #999999 out of 302 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #999999 out of 302 companies for Debt-to-EBITDA. This places NurExone Biologic in the lower half of its industry. The industry median Debt-to-EBITDA is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.29, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NurExone Biologic. For the Biotechnology industry, the median Debt-to-EBITDA is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NurExone Biologic's current Debt-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Debt-to-EBITDA of -0.01. The current Debt-to-EBITDA is -0.01. NurExone Biologic's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Debt-to-EBITDA is -0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
38GF Score
Get the complete analysis for FRA:J90
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J90 has been successfully added to your 
